| Clinical data | |
|---|---|
| Trade names | Omegaven |
| AHFS/Drugs.com | Professional Drug Facts |
| License data |
|
| Pregnancy category |
|
| Dependence liability | Intravenous |
| Drug class | Intravenous nutritional products |
| ATC code |
|
| Legal status | |
| Legal status | |
Fish oil, sold under the brand name Omegaven, is a fatty acid emulsion.[2] It is used for total parenteral nutrition (feeding directly into a venous catheter), e.g. in short bowel syndrome.[2] It is rich in omega-3 fatty acids.[2]
It has gained popularity in children in preference to the more commonly used Intralipid after case reports that it reduced the risk of liver damage.[3]
A 2007 study indicated that the use of Omegaven may be an appropriate intervention strategy for newborns with a very low birth weight, gastrochisis, and jejunal atresia.[4]
A clinical trial exploring the use of fish oil as an adjunct to parenteral nutrition in surgical intensive care units at National Taiwan University Hospital completed in March 2007.[5]
Although the use of fish oil triglycerides in children in the United States is experimental, the use of it in adults in Europe is less controversial.[6] In European studies, fish oil triglycerides have been associated with a reduction in psoriasis, when contrasted to administration of omega-6 fatty acid Lipoven.[7] Fish oil triglycerides have also been associated with reduced mortality and antibiotic use during hospital stays.[8]
Fish oil triglycerides was approved for use in the United States on July 27, 2018,[9] and is available to patients on the US market by prescription effective November 15, 2018.[10]
References
- ^ a b "Fat emulsion Use During Pregnancy". Drugs.com. 4 May 2020. Retrieved 12 May 2020.
- ^ a b c d "Omegaven- fish oil injection, emulsion". DailyMed. 6 August 2018. Retrieved 13 May 2020.
- ^ Gura KM, Duggan CP, Collier SB, et al. (2006). "Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management". Pediatrics. 118 (1): e197–201. doi:10.1542/peds.2005-2662. PMID 16818533. S2CID 46567040.
- ^ Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK (2007). "Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease". Journal of Perinatology. 27 (5): 284–90. doi:10.1038/sj.jp.7211686. PMID 17344923.
- ^ Clinical trial number NCT00172198 for "Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU." at ClinicalTrials.gov
- ^ A Doctor's Push For Drug Pits Him Against Its Maker at The Wall Street Journal
- ^ Mayser P, Grimm H, Grimminger F (2002). "n-3 fatty acids in psoriasis". Br. J. Nutr. 87. Suppl 1: S77–82. doi:10.1079/bjn2001459. PMID 11895157.
- ^ Heller AR, Rössler S, Litz RJ, et al. (2006). "Omega-3 fatty acids improve the diagnosis-related clinical outcome". Crit. Care Med. 34 (4): 972–9. doi:10.1097/01.CCM.0000206309.83570.45. PMID 16484909. S2CID 32537029.
- ^ "Drug Approval Package: Omegaven (fish oil triglycerides)". U.S. Food and Drug Administration (FDA). 24 August 2018. Retrieved 12 May 2020.
- ^ Research, Center for Drug Evaluation and. "Investigational New Drug (IND) Application - How to request Omegaven for Expanded Access Use". www.fda.gov. Retrieved 2019-02-15.
External links
- "Omegaven". Drug Information Portal. U.S. National Library of Medicine.
- Cooke, Robert (2006-07-03). "How fish oil may have saved babies' lives". The Boston Globe. Retrieved 2007-08-22.
- "Fishing for the Right Solution" at Children's Hospital Boston
- "The Right Kind of Oil" at Children's Hospital Boston
- Team on a Mission at Toronto Star
- Old Fashioned Lifeline Boston Globe 1/9/2009
- rockcenter.nbcnews.com: drug treatment omegaven that could save infants lives not yet approved by fda